Moderna CEO Bancel 谈 intismeran 肿瘤疫苗 III 期成功后下一步
STAT+: Moderna CEO on what’s next after success in cancer vaccine
在 ESMO 年会现场，Moderna CEO Stéphane Bancel 接受 STAT 采访，谈及个体化 mRNA 疗法 intismeran 在黑色素瘤 III 期研究中取得成功后的下一步，以及这一结果对公司研发和商业策略的影响。该研究由 Moderna 与 Merck 合作推进，Bancel 称团队已在该项目上投入十年。原文为 STAT+ 付费内容，访谈正文未完整公开。
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.
MADRID — Moderna CEO Stéphane Bancel had every reason to be smiling and happy on a brilliantly sunny, Saturday afternoon here in Spain’s capital. In a couple of hours, a decade of the company’s research — boosted by a partnership with Merck — was going to culminate in the presentation of the first Phase 3 study to successfully demonstrate that a customized mRNA-based therapy called intismeran could improve outcomes for patients with melanoma.
“It’s an amazing feeling,” he told STAT from the sidelines of the European Society for Medical Oncology annual meeting. “We’ve been working on intismeran for 10 years. Most people in the field thought this was never going to work, and many people had tried cancer vaccines before. But we were convinced, so it has been really special to be able to see all this work by so many people coming together to help patients.”
In a wide-ranging interview, Bancel spoke to STAT about what’s next for intismeran, and how the drug’s success impacts the company’s R&D and business strategies. The conversation has been condensed and edited for clarity.
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
来源：STAT News · statnews.com